newsfilter
← Latest News
Business Wire·

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and protection from CDI recurrence Topline data for the ongoing Phase 3